rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    MAZE
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Maze Therapeutics at Jefferies Global Healthcare Conference: pipeline gains
      Nov 17Investing.comMAZEJEF
      Maze Therapeutics: Vertex Is Building The Road, And Maze Gets To Drive On It
      Nov 13Seeking AlphaMAZE
      Maze Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights
      Nov 9Yahoo FinanceMAZE
      Maze Therapeutics earnings in focus as kidney drug rivalry heats up
      Nov 4Investing.comMAZE
      Wall Street Analysts Predict a 93.92% Upside in Maze Therapeutics, Inc. (MAZE): Here's What You Should Know
      Nov 4Yahoo FinanceMAZE
      Maze Therapeutics to Participate in Upcoming Investor Conferences
      Nov 3Yahoo FinanceMAZE
      What Makes Maze Therapeutics, Inc. (MAZE) a New Buy Stock

      Maze Therapeutics, Inc. (MAZE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

      Oct 19Yahoo FinanceMAZERNTX
      How Much Upside is Left in Maze Therapeutics, Inc. (MAZE)? Wall Street Analysts Think 123.39%
      Oct 19Yahoo FinanceMAZE
      Canaccord initiates Maze Therapeutics stock rating at Buy on kidney drug potential
      Oct 19Investing.comMAZE
      Canaccord Genuity Initiates Maze Therapeutics at Buy With $75 Price Target
      Oct 19Yahoo FinanceMAZE
      Maze Therapeutics CEO Jason Coloma sells $932,259 in Maze shares
      Oct 18Investing.comMAZE
      Maze Therapeutics to Present Data from MZE829 and MZE782 Programs at ASN Kidney Week 2026
      Oct 6Yahoo FinanceMAZE
      Could Vertex Pharmaceuticals (VRTX)’s Kidney Breakthrough Unlock a New Opportunity for Maze Therapeutics (MAZE)?

      On September 22, Truist analyst Danielle Brill identified a “significant positive readthrough” for Maze Therapeutics, Inc. (NASDAQ:MAZE) following positive Phase 2 topline data from Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). The data validates APOL1 inhibition in classic APOL1-mediated kidney disease (AMKD), supporting an addressable population of over 100,000 patients. Truist reiterated a Buy rating and $64 target […]

      Sep 29Yahoo FinanceMAZEVRTX
      Maze Therapeutics (MAZE) Shares Moved, So What Is Driving Attention Now?

      Fresh Coverage Puts Maze Therapeutics in Focus Maze Therapeutics (MAZE) moved higher in pre-market trading on 23 September after CIBC began covering the clinical-stage kidney and metabolic disease specialist, with the share reaction unfolding alongside new kidney data from Vertex Pharmaceuticals. Recent trading has been choppy for Maze Therapeutics, with a 1-day share price return that declined 6.69% following a 7-day share price return up 11.82%. The year-to-date share price return is down...

      Sep 25Yahoo FinanceMAZE
      Analysts Offer Insights on Healthcare Companies: Maze Therapeutics, Inc. (MAZE), Viking Therapeutics (VKTX) and Aytu BioScience (AYTU)

      Detailed price information for Viking Thera (VKTX-Q) from The Globe and Mail including charting and trades.

      Sep 24The Globe and MailMAZE
      Maze Therapeutics Shares Rise 2.9% After CIBC Initiates Coverage

      Maze Therapeutics (NASDAQ:MAZE) shares rose 2. 9% in pre-market trading after CIBC initiated coverage of the clinical-stage biopharmaceutical company with an Outperformer rating and a $50 price target.

      Sep 23Yahoo FinanceMAZECM
      Why is Maze Therapeutics stock climbing today?
      Sep 23Investing.comMAZE
      Correction: Citigroup Initiates Maze Therapeutics at Buy With $50 Price Target

      (Corrects brokerage firm in headline.) Maze Therapeutics (MAZE) has an average rating of buy and

      Sep 23Yahoo FinanceMAZE
      BTIG Initiates Maze Therapeutics at Buy With $50 Price Target

      Maze Therapeutics (MAZE) has an average rating of buy and mean price target of $62.55, according to

      Sep 23Yahoo FinanceMAZE
      Analysts Are Bullish on Top Healthcare Stocks: Vertex Pharmaceuticals (VRTX), Maze Therapeutics, Inc. (MAZE)

      Detailed price information for Maze Therapeutics Inc (MAZE-Q) from The Globe and Mail including charting and trades.

      Sep 23The Globe and MailMAZE
      The Surprise That Sent Vertex — And Its Chief Rival — Soaring

      Vertex stock popped Tuesday — while shares of rival Maze Therapeutics skyrocketed — on a surprise expansion for their kidney disease drugs.

      Sep 22Investor's Business DailyMAZE
      Vertex’s Kidney Drug Success Sparks a 22% Surge for This Rival Biotech
      Sep 22Barron'sMAZEVRTX
      Twin Moves: VRTX Rises On Kidney Disease Trial Results, MAZE Rallies Harder
      Sep 22Yahoo FinanceMAZE
      On Holding, Viking Therapeutics, Shopify And Other Big Stocks Moving Higher On Tuesday
      Sep 22BenzingaMAZEVKTXSHOP
      Maze Therapeutics stock hits 52-week low at 22.44 USD
      Sep 18Investing.comMAZE
      Maze Therapeutics at H.C. Wainwright conference: pipeline nears key tests
      Sep 15Investing.comMAZE
      Maze Therapeutics Chief Medical Officer Dumps Entire Direct Stake in the Company for $255,000

      The executive liquidated his entire direct holdings as the stock plunged about 50% from its 52-week high.

      Sep 11Yahoo FinanceMAZE
      Analysts Are Bullish on These Healthcare Stocks: Maze Therapeutics, Inc. (MAZE), Mirum Pharmaceuticals (MIRM)

      Detailed price information for Protagonist Therapeutics Inc (PTGX-Q) from The Globe and Mail including charting and trades.

      Sep 11The Globe and MailMAZE
      Maze Therapeutics at Citi summit: early data, bigger tests ahead
      Sep 10Investing.comMAZE
      Maze Therapeutics at Wells Fargo conference: pipeline gains pace
      Sep 9Investing.comMAZE
      Maze therapeutics president, R&D & CMO, sells $254,501 in shares
      Sep 8Investing.comMAZE
      Maze Therapeutics (MAZE) Stock Analysis Report | Financials & Insights
      Sep 6BenzingaMAZE
      Maze Therapeutics to Participate in Three Upcoming Investor Conferences

      SOUTH SAN FRANCISCO, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced that company management will participate in three upcoming investor conferences: Wells Fargo 21st Annual Healthcare Conference; fireside chat on Wednesday, September 9, 2026, at 9:30 a.m. ETCiti 2026 Biopharma Back to School Summit; fireside

      Sep 2Yahoo FinanceMAZE
      Maze Therapeutics CSBO Dandekar divests $206,823 of common stock
      Aug 31Investing.comMAZE
      Maze Therapeutics: Intriguing Kidney Disease Assets Put This On The Watchlist
      Aug 26Seeking AlphaMAZE

      This is the newest page. Registered accounts read further back.